Terns Pharmaceuticals Inc
TERN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.93B
Close$
$5.62
89.4% downside
Current Fair Value
89.4% downsideOvervalued by 89.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.93 Billion |
|---|---|
| Enterprise Value | $4.41 Billion |
| Earnings per Share | $-1.03 |
| Beta | -0.38 |
| Outstanding Shares | 93,166,571 |
Return
| Return on Equity | -9.56% |
|---|---|
| Return on Assets | -9.39% |
| Return on Invested Capital | -10.92% |
Valuation & Multiples
| P/E Ratio | -68.77 |
|---|---|
| PEG | -845.96 |
| Price to Sales | - |
| Price to Book Ratio | 5.3 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -40.06 |
| Enterprise Value to Net Income | -46 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.30
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.64, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.6409▲ 44.93% |
|---|---|
| Total Calls | 7,168,620▲ 465.66% |
| Total Puts | 4,594,600▲ 1791.56% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 133.92%▲ 2.34% |
|---|---|
| Total Invested | $6.56B▲ 32.53% |
| Investors Holding | 358▲ 102.00% |
About Terns Pharmaceuticals Inc
30 employees
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chr...